Phase I/II Study of LDE225 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer.
Esther N PijnappelNienke Petronella Maria WassenaarOliver J Gurney-ChampionRemy KlaassenKoen van der LeeMarjolein C H Pleunis-van EmpelDick J RichelMarie C LegdeurAart J NederveenHanneke W M van LaarhovenJohanna W WilminkPublished in: Cancers (2021)
LDE225 in combination with gemcitabine and nab-paclitaxel was well-tolerated in patients with metastatic PDAC and has promising efficacy after prior treatment with FOLFIRINOX. Quantitative MRI suggested that LDE225 causes increased tumor diffusion and works particularly well in patients with poor baseline tumor perfusion.